Utomilumab

Modify Date: 2025-11-02 19:33:39

Utomilumab structure	Common Name	Utomilumab
	CAS Number	1417318-27-4	Molecular Weight	388.42
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₇H₂₄N₈O₃	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Utomilumab

Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphomas (NHL)[1][2].

Name	Utomilumab

Description	Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphomas (NHL)[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
References	[1]. Anthony W Tolcher, et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Sep 15;23(18):5349-5357. [2]. Ajay K Gopal, et al. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20⁺ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

References

[1]. Anthony W Tolcher, et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Sep 15;23(18):5349-5357.

[2]. Ajay K Gopal, et al. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20⁺ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534.

Molecular Formula	C₁₇H₂₄N₈O₃
Molecular Weight	388.42

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Utomilumab

Use of Utomilumab

Names

Utomilumab Biological Activity

Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.